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Abstract
Epidermal growth factor (EGF) is one of the ErbB receptor ligands implicated in schizophrenia neuropathology as well as in
dopaminergic development. Based on the immune inflammatory hypothesis for schizophrenia, neonatal rats are exposed to
this cytokine and later develop neurobehavioral abnormality such as prepulse inhibition (PPI) deficit. Here we found that the
EGF-treated rats exhibited persistent increases in tyrosine hydroxylase levels and dopamine content in the globus pallidus.
Furthermore, pallidal dopamine release was elevated in EGF-treated rats, but normalized by subchronic treatment with
risperidone concomitant with amelioration of their PPI deficits. To evaluate pathophysiologic roles of the dopamine
abnormality, we administered reserpine bilaterally to the globus pallidus to reduce the local dopamine pool. Reserpine
infusion ameliorated PPI deficits of EGF-treated rats without apparent aversive effects on locomotor activity in these rats.
We also administered dopamine D1-like and D2-like receptor antagonists (SCH23390 and raclopride) and a D2-like receptor
agonist (quinpirole) to the globus pallidus and measured PPI and bar-hang latencies. Raclopride (0.5 and 2.0 mg/site)
significantly elevated PPI levels of EGF-treated rats, but SCH23390 (0.5 and 2.0 mg/site) had no effect. The higher dose of
raclopride induced catalepsy-like changes in control animals but not in EGF-treated rats. Conversely, local quinpirole
administration to EGF-untreated control rats induced PPI deficits and anti-cataleptic behaviors, confirming the
pathophysiologic role of the pallidal hyperdopaminergic state. These findings suggest that the pallidal dopaminergic
innervation is vulnerable to circulating EGF at perinatal and/or neonatal stages and has strong impact on the D2-like
receptor-dependent behavioral deficits relevant to schizophrenia.
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Introduction
Epidermal growth factor (EGF) and structurally related EGF-
like peptides (such as neuregulin-1; NRG1) regulate GABAergic
and dopaminergic development [1–5]. Genetic studies suggest that
the genomic mutation or polymorphism for EGF, NRG1 and their
receptors (ErbBs) is associated with schizophrenia risk [6–9].
Changes in the expression levels of EGF, NRG1 and ErbBs are
also found in postmortem brains and peripheral blood of
schizophrenia patients [10–13]. Both EGF and NRG1 are known
to influence their own receptor binding and provoke signal cross-
talks of other ErbB subtype(s) via ErbB1-4 receptor heterodimir-
ization [14], [15]. Accordingly, abnormal ErbB signaling might be
one of key features in schizophrenia neuropathology and/or
etiology, although the pathophysiological nature of ErbB signaling
in schizophrenia is largely unresolved [16], [17].
Among many environmental factors implicated in schizophrenia
etiology, maternal viral infection and obstetric complications are
suggested to play an important role in regulating vulnerability to
schizophrenia [18–21]. These inflammatory insults often evoke
abnormalcytokinesignalingand perturbnormalbraindevelopment
[18], [21]. For instance, EGF levels in the amniotic fluid can
sometimes reach the order of a microgram per liter, which is
sufficient to occupy almost all EGF receptors (ErbB1) in the human
fetus and lead to unfavorable uterine contractions and pre-term
labor [22], [23]. To evaluate the impact of prenatal and perinatal
ErbB hyper–signaling on neurobehavioral development, various
ErbB ligands such as EGF and NRG1 were subcutaneously
administered to rodent pups as their neurodevelopmental period
matches the second trimester of human fetus having immature
blood–brain barrier and initiating glial proliferation [24]. We found
that ErbB ligands can penetrate the immature blood–brain barrier
and reach brain neurons, resulting in various behavioral impair-
ments at the post-pubertal stage [25]. For example, rats challenged
with EGF as neonates display behavioral abnormalities in acoustic
prepulse inhibition (PPI), latent inhibition of learning, social
interaction, and methamphetamine sensitivity [26], [27]. The
magnitude of the behavioral deficits, however, depends upon the
type of ErbB ligands administered and the genetic background of
the host animals [4], [27], [28]. In rodents, therefore, abnormal
ErbB signaling in the prenatal and/or perinatal stage results in the
neurobehavioral deficits [26–28] and/or dopaminergic abnormal-
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mechanism underlying the individual deficits remains to be
clarified.
Here, we prepared the animal model for schizophrenia by
subcutaneously injecting EGF to newborn rats and studied the
mechanism for their PPI abnormality. Based upon our latest
finding on the neurotrophic interactions between EGF signaling
and dopamine [5], [29], [30], we mainly characterized dopami-
nergic neuropathology of these rats using neurochemical and
anatomical approaches. Furthermore we explored the pathologic
mechanism underlying their behavioral deficits by pharmacolog-
ically manipulating local dopamine transmission.
Results
Upregulation of dopaminergic markers in the globus
pallidus continuing until adulthood
At the early postnatal stage of rats, EGF is verified to reach the
brain through the immature blood-brain barrier and promote
phenotypic development of midbrain dopaminergic neurons,
leading to neurobehavioral abnormalities relevant to schizophre-
nia [26], [31]. However, there was a question of whether the
neurotrophic influences on dopaminergic neurons can continue
until the post-pubertal stage when rats develop the neurobehav-
ioral abnormalities [26]. To address this question, here, we
quantitated and compared protein levels of tyrosine hydroxylase
(TH; a rate-limiting enzyme for dopamine synthesis) in various
brain regions of EGF-treated and control rats at their adult stage
using enzyme immunoassay (ELISA) [32], [33] (Fig. 1A). In the
globus pallidus, TH protein levels were significantly higher in
EGF-treated rats than in control rats (P=0.035). There were no
significant differences in the other brain regions in this ELISA
(Fig. 1A). In the globus pallidus, there was concomitant elevation
of tissue dopamine content (P=0.030) and its metabolites,
DOPAC (P=0.014) (Fig. 1B, C) and HVA (P=0.019, data not
shown). We confirmed the pallidal hyperdopaminergic state by
immunoblotting; protein levels of TH and VMAT2, but not those
of DbH (a maker for noradrenergic neurons), were significantly
elevated in EGF-treated rats at the adult stage (Fig. 1D).
To determine whether the TH increase in the globus pallidus
accompanies morphological alterations, we investigated the
neuroanatomical features of dopaminergic fibers and terminals
in EGF-treated rats (Fig. 2). In contrast to the neurochemical
alterations, the anatomical difference in TH immunoreactivity was
less marked. The density of TH-immunoreactive fibers was higher
in EGF-treated rats only in the lateral area of medial and caudal
globus pallidus neighboring the striatum. In rostral globus pallidus,
however, we failed to detect the difference (data not shown).
Antipsychotic effects on extracellular dopamine levels in
the globus pallidus of EGF-treated rats
Sensorimotor gating involves pallidal function and dopaminer-
gic transmission [34]. We next monitored extracellular dopamine
levels in the globus pallidus using a microdialysis technique and
estimated a link between local dopamine concentration and
sensorimotor gating (Fig. 3A). In agreement with the previous
results [26], neonatal EGF treatment reduced PPI scores at the
adult stage and an atypical antipsychotic agent ameliorated the
PPI reduction (Fig. 3B). EGF-treated animals also exhibited an
increase in pulse alone-startle amplitude compared with control
animals but not with risperidone-treated animals [F(2,33)=3.61,
P=0.038] (Fig. 3C). We found that basal extracellular dopamine
levels (1.5260.19 nM) in pallidal dialysates from EGF-treated rats
were significantly elevated than in those from controls
(0.8560.06 nM; P,0.001, N=11–13) but decreased by subchro-
nic treatment with risperidone (0.6760.08 nM; P,0.001, N=11)
[F(2,33)=14.8, P,0.001] (Fig. 3D). Following potassium depo-
larization stimuli, extracellular dopamine levels were also elevated
in EGF-treated rats but not in risperidone-administered EGF-
treated rats [F(2,33)=5.07, P=0.008, N=11–13]. The release
difference at both the basal and evoked states suggests that EGF
altered the capacity of net dopamine release but not the
excitability of dopamine terminals. Of note, the overall changes
in extracellular dopamine levels exhibited an opposite trend to that
of the changes in PPI levels in the above experiments. These
Figure 1. Effects of neonatal EGF challenge on tyrosine
hydroxylase and dopamine metabolism at the adult stage.
EGF or cytochrome c (control) was daily injected (s.c.) into neonatal rats
from PND2 to PND10, and rats were bred until adulthood (PND 56). (A)
Levels of tyrosine hydroxylase (TH) immunoreactivity in brain tissue
homogenates were determined by ELISA and presented as a ratio of
control levels (mean 6 SEM). Tissue contents of dopamine (B) and its
metabolite DOPAC (C) were measured by HPLC. (D) Tissue lysates from
the globus pallidus of EGF rats and controls (8 weeks old, N=4) were
subjected to immunoblotting for antibodies directed against TH,
vesicular monoamine transporter 2 (VMAT2), dopamine beta hydrox-
ylase (DbH), dopamine D1 receptor (D1R), dopamine D2 receptor (D2R),
and b-actin (an internal control). Immunoreactivity was measured by
densitometric analysis and its percentage ratio to that of control rats
was calculated (mean 6 SEM). Abbreviations; medial prefrontal cortex
(prelimbic cortex; mPFC), striatum (STR), nucleus accumbens (NAC),
cingulate cortex (Cg), globus pallidus (GP), amygdala (AMG), hypothal-
amus (Hyp), subthalamic nucleus (STN), and substantia nigra (SN).
*P,0.05, **P,0.01 by two-tailed t-test.
doi:10.1371/journal.pone.0025831.g001
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release might be associated with the PPI decrease in this model.
Local reserpine administration to the globus pallidus
ameliorates prepulse inhibition deficits
To confirm our hypothesis, we administered reserpine (an
inhibitor of VMAT) or vehicle to reduce local dopamine content
in synaptic vesicles and measured prepulse inhibition (Fig. 4A). A
three-way ANOVA with EGF treatment and reserpine challenge
as the between-subjects factors and prepulse intensity as the
within-subjects factor revealed a significant interaction between
EGF treatment and reserpine challenge [F(1,29)=7.81, p=0.009].
Repeated Fisher’s LSD revealed that reserpine challenge signifi-
cantly improved PPI scores in EGF rats (P=0.012). In contrast,
reserpine did not alter PPI scores of control rats or pulse-alone
startles of both groups of rats. Following the behavior tests, we
monitored local dopamine contents to ascertain the regional
specificity of the reserpine action (Fig. 4B). The dose of reserpine
reduced the dopamine pool in the globus pallidus of EGF rats
(P,0.001) but not in the neighboring striatum of EGF rats or in
these regions of control rats.
There was a significant difference in pulse-alone startle amplitude
between EGF-treated and control rats [F(1,28)=16.4, P,0.001 for
EGF]. Our current design to evaluate reserpine action on %PPI
might be inappropriate due to the basal difference in pulse-alone
startle amplitudes of EGF and control rats [35]. We prepared
another set of animals and gave the lower intensity of tone stimuli
(110 dB for main pulses) to EGF-treated rats (Fig. 4C, D). The PPI
difference between EGF and control groups as well as the
risperidone effectstillremained,eventhoughtherewasnosignificant
difference in the amplitudes of pulse-alone startles among groups.
Figure 2. Immunohistochemical analysis of tyrosine hydroxy-
lase-positive fibers and terminals in the globus pallidus.
Coronal sections of the striatum containing medial and caudal globus
pallidus (1.2 and 1.6 mm posterior from the bregma) were prepared
from control and EGF-treated rats and immunostained with anti-TH
antibody (N=3–4 rats per group). TH-immunoreactive fibers in medial
(A, B) and caudal (C, D) globus pallidus of control (A, C) and EGF rats (B,
D) are shown. A lateral area of the globus pallidus is marked with a
window, enlarged 2-fold, and presented in the top-right corner of each
picture. ST; striatum, GP; globus pallidus, ic; internal capsule. Scale bar,
500 mm.
doi:10.1371/journal.pone.0025831.g002
Figure 3. Pallidal dopamine release enhanced in EGF-treated
rats and normalized with risperidone. Neonatal rats were treated
with EGF or cytochrome c (control) as described in Figure 1. Risperidone
(1 mg/kg, i.p.) was administered to some of the EGF-treated rats for 14
days at the adult stage. (A) The location of dialysis probe was examined
and is shown in rat brain atlas. Six rats were excluded for incorrect probe
placement. The digit represents the distance from the bregma. (B) PPI
levels were monitored in control, EGF-treated and EGF+risperidone-
treated animals following microdialysis. (C) Pulse-alone startle responses
and PPI levels were monitored in control, EGF-treated and EGF+risper-
idone-treated animals following microdialysis. (D) Basal concentrations of
dopamine in dialysates were monitored for 150 min, dopamine release
was evoked by perfusion of 80 mM KCl over 60 min (solid bar), and then
monitored over 150 min. Data represent dopamine concentrations in 30-
min fractions (nM, mean 6 SEM, N=11–13 rats per group). There was a
significant interaction between time and dopamine release
[F(12,198)=2.72, P=0.002]. *P,0.05, ***P,0.001, compared with
controls and ++P,0.01, compared with EGF-treated rats by Fisher’s LSD.
doi:10.1371/journal.pone.0025831.g003
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assessed the exploratory motor behaviors of reserpine-injected
animals (Fig. 5A, B). We found no significant influence of reserpine
on horizontal movement. As EGF-treated rats are known to exhibit
a decrease in social interaction scores [26], we also evaluated the
effects of reserpine on social behaviors following the above
exploratory locomotor test (Fig. 5C). Two-way ANOVA for sniffing
duration revealed a significant main effect of EGF [F(1,30)=17.8,
P,0.001] but no main effect of reserpine or no interaction between
EGF and reserpine. The same statistical conclusion was drawn for
sniffing counts as well. These results indicate that reserpine-induced
pallidal dopamine reduction affected PPI levels of EGF rats, but did
not influence their motor function or deficits in social behaviors.
Effects of pallidal dopamine D2-like receptor blockade
and activation on prepulse inhibition
To test the possibility that the reserpine effects on PPI might
result from its influences on the noradrenergic or serotonergic
systems, we manipulated local dopaminergic transmission using
dopamine receptor antagonists. We bilaterally administered a
dopamine D1-like receptor antagonist, SCH23390 (0.5 mg and
2 mg per site), or a dopamine D2-like receptor antagonist,
raclopride (0.5 mg and 2 mg per site), to the globus pallidus
(Fig. 6A). SCH23390 failed to affect PPI scores at any dose in both
groups of rats (Fig. 6B). In contrast, raclopride had differential
effects in EGF and control rats [F(2,43)=3.91 for EGF6raclo-
pride dose, P=0.028] (Fig. 6C). Post-hoc testing revealed that
raclopride injection significantly ameliorated the PPI deficits of
EGF rats (P=0.019 and 0.043 for 0.5 mg and 2 mg raclopride,
respectively) but not affected PPI levels of control rats. Similar to
the results of the reserpine experiment, vehicle-treated control rats
failed to react to the D2-like receptor antagonist at any dose.
To address whether a hyperdopaminergic state in the globus
pallidus is sufficient to induce PPI deficits, we examined the effects
of local stimulation of D2-like receptors. The bilateral challenge of
naı ¨ve rats with quinpirole, a D2-like receptor agonist (5 mg per
site), markedly disrupted PPI [F(1,16)=6.50, P=0.022] without
altering pulse-alone startle (Fig. 7). These results support our
Figure 4. Effects of pallidal reserpine infusion on prepulse
inhibition. (A) Startle responses of EGF and control (CON) rats were
triggered with 120-dB tone pulse and PPI scores were measured with
75-, 80-, and 85-dB prepulse stimuli 120 min after local vehicle or
reserpine infusion to both hemispheres of the globus pallidus. Pulse-
alone startle responses to a 120-dB tone were measured in arbitrary
units and are shown in the inset. (C) To match pulse-alone startle
responses between EGF and control rats, 110-dB and 120-dB pulses
were given to EGF and control rats, respectively, as shown in the insert.
Following PPI test in (A) and (C), dopamine content was measured in
the globus pallidus (GP) and neighboring striatum and shown in (B) and
(D), respectively. Bars indicate mean 6 SEM (N=8–9 each). *P,0.05,
**P,0.01, ***P,0.001, compared with vehicle-infused control rats;
++P,0.01, +++P,0.001, compared with vehicle-infused EGF rats by
Fisher’s LSD.
doi:10.1371/journal.pone.0025831.g004
Figure 5. Influences of pallidal reserpine infusion on locomotor
activity and social interaction. EGF and control (CON) rats received
local reserpine- or vehicle-infusion to both hemispheres of the GP. (A)
Cannula placement was confirmed in fixed brains, and two out of 36
rats were excluded from the final data analysis due to incorrect cannula
placement. (B) Two hours after pallidal infusion, rats were placed in the
automated activity monitoring chamber for 60 min. Data represent
horizontal movement (cm) for every 5 min (mean 6 SEM, N=7–9 for
each group). (C) Following locomotor test, an unfamiliar male rat was
placed in the same chamber. The number and duration of sniffing
behaviors of operated rats were counted for 10 min. Bars indicate mean
6 SEM (N=8–9 for each group). **p,0.01, ***p,0.001 by Fisher’s LSD,
compared with vehicle-infused controls.
doi:10.1371/journal.pone.0025831.g005
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responsible for the PPI deficits.
Difference in cataleptic actions of a D2-like receptor
antagonist on EGF-treated and control rats
Because dopamine D2-like receptor blockade is known to induce
cataleptic behaviors [36], we used the bar-hang immobility test to
estimate the effects of the antagonist on catalepsy scores (Fig. 8A).
Prior to drug administration, EGF-treated and control rats were
subjected to the first session of the bar-hang test. There was a
significant basal difference in bar-hang latency [F(1,43)=19.0,
P,0.001forEGF](Fig.8B).PallidalinfusionoftheD2-likereceptor
antagonist produced differential effects on EGF and control rats
[F(2,44)=9.07, P,0.001 for raclopride dose6EGF]. The higher
doseofraclopridesignificantlyincreasedbar-hanglatencyincontrol
rats (P,0.001) but not in EGF rats. Thus, EGF rats appear to be
insensitive to the given doses of the D2-like receptor blocker in this
test. These results rule out the possibility that the observed
raclopride effects on PPI in EGF-treated rats might reflect its
cataleptic action. Moreover, this experiment revealed the lower
sensitivity of EGF-treated rats to pallidal D2-like receptor blockade.
Of note, the pallidal infusion of the D2-like receptor agonist
quinpirole to naı ¨ve rats significantly diminished the bar-hang
latency, compared with the latency before injection [F(2,24)=4.54,
P=0.021] (Fig.8C).Thebar-hanglatencyofquinpirole-infusedrats
was significantly shorter than that of vehicle-infused controls
(P,0.001) and indistinguishable from that of EGF-treated rats.
Alltheseresults suggest that pallidal dopaminergic signals negatively
regulate bar-hang latency. Therefore, the shorter bar-hung latency
of EGF-treated rats supports our argument that pallidal dopamine
function was up-regulated in these animals.
Discussion
In the present investigation, we attempted to address the
question of how EGF challenge at the perinatal stage alters later
Figure 6. Effects of pallidal infusion of dopamine receptor
antagonists on PPI deficits. Different doses of the D1-like receptor
antagonist [SCH23390; 0 mg (vehicle), 0.5 mgo r2mg per site] or the D2-
like receptor antagonist [raclopride; 0 mg (vehicle alone), 0.5 mgo r2mg
per site] were administered to both hemispheres of the globus pallidus
of EGF and control rats. (A) Cannula placement was confirmed in fixed
brains, and four out of 69 rats were excluded from the final data analysis
due to incorrect cannula placement. Rats receiving SCH23390 (B) or
raclopride (C) were subjected to PPI test with 75-, 80- and 85-dB
prepulse stimuli combined with a 120-dB startle tone. Pulse-alone
startle responses to a 120-dB tone were measured in arbitrary units and
are shown in the inset. Bars indicate mean 6 SEM (N=8–9 for each
group). Data of rats receiving vehicle alone (control) were shared in (B)
and (C). *P,0.05, **P,0.01, compared with vehicle-infused controls;
+P,0.05, ++P,0.01, compared with vehicle-infused EGF rats by Fisher’s
LSD.
doi:10.1371/journal.pone.0025831.g006
Figure 7. Effects of pallidal infusion of a dopamine D2-like
agonist on PPI. A dopamine D2-like agonist, quinpirole (QUIN) (5 mg
per site), or vehicle was administered to both hemispheres of the GP of
naı ¨ve rats. (A) Cannula placement was confirmed in fixed brains, and
one out of 18 rats was excluded from the final data analysis due to
incorrect cannula placement. Fifteen minutes after quinpirole injection,
pulse-alone startles (B) and PPI scores (C) were measured with 75-, 80-
and 85-dB prepulse stimuli combined with a 120-dB startle tone. Bars
indicate mean 6 SEM (n=8 or 9 each). *p,0.05, **p,0.01, compared
with vehicle-infused controls by Fisher LSD.
doi:10.1371/journal.pone.0025831.g007
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ioral traits. The present analyses of this model provided us with the
following information: 1) The hyperdopaminergic phenotype was
maintained in the globus pallidus until adulthood. 2) The amounts
of pallidal dopamine release were elevated at the adult stage of
EGF-treated rats and normalized with antipsychotic treatment. 3)
The reserpine-driven reduction in pallidal dopamine pool
ameliorated the PPI deficits of EGF-treated rats. 4) The D2-like
receptor blocker also normalized PPI levels of EGF-treated rats
without affecting the catalepsy index. 5) Conversely, local
administration of the D2-like receptor agonist to naı ¨ve rats caused
deficits in PPI and bar-hang latency similar to that seen in EGF-
treated rat. These results reveal that EGF exposure to rat pups
produces persistent neurotrophic influences on the nigropallidal
dopamine neurons and their functions. Thus, we postulate that the
behavioral deficits of this EGF model, in part, can be ascribed to
the D2 receptor-dependent hyperdopaminergic states of this basal
ganglia circuit.
Trophic actions and selectivity of epidermal growth
factor peripherally administered
EGF and other ErbB ligands (such as neuregulin-1) are
neurotrophic not only for midbrain dopaminergic neurons but
also for GABAergic neurons and glial cells [1–5], [37], [38].
Although we have been investigating the phenotypic influences of
peripheral EGF challenges on developing GABAergic and glial
cells, these effects did not persist until the adult stage [2], [26],
[31]. As such, the hyperdopaminergic influence found in the
present investigation is the sole phenotypic change that we have
detected in the adult stage of EGF-treated rats. Similar to this
study, we find long-lasting influences of neonatal neuregulin-1
challenges on the dopamine system [4]. With the given wide-
spread action of these ErbB ligands, however, we cannot rule out
the possibility that undetected changes in GABAergic or glial
phenotype or function still remain in this model [2], [5], [37], [38].
Individual dopaminergic systems of mesostriatal, mesolimbic,
and mesofrontocortical pathways appear to be differentially
regulated by individual neurotrophic factors [5], [37–39]. Among
these neurons, a subset of dopaminergic neurons in the ventral tier
of the substantia nigra pars compacta mainly express the EGF
receptor (ErbB1), which constitute of highly branched dopami-
nergic neurons in the mesostriatal and pallidal pathways [5], [40],
while the neuregulin-1 receptors (ErbB4) are most enriched in
mesofrontocortical dopamine neurons [37]. Therefore, it is likely
that mesostriatal dopaminergic population responded to exoge-
nous EGF and contributed to the pallidal hyperdopaminergic
states of the present animal model. In contrast to the neurochem-
ical changes, the number of dopamine terminals in the globus
pallidus was less remarkable. In this context, the neurotrophic
feature of EGF on dopamine neurons remains to be fully
characterized; its effects on cell survival, phenotypic enhancement,
or terminal arborization. Our preliminary study failed to detect
apparent difference in the number of dopamine neurons (data not
shown).
In contrast to the present EGF model, the mice treated with
neuregulin-1 as neonates, in which dopaminergic influences are
most pronounced in the prelimbic cortex, exhibit less marked
deficits in PPI but more severe impairments in social behaviors [4],
[41]. The difference of the behavioral traits between the two
models might reflect the distinct neurotrophic actions of EGF and
neuregulin-1 on these cell subpopulations.
Neuropathological implication of the globus pallidus for
schizophrenia and its animal model
The globus pallidus is part of the indirect pathway of the basal
ganglia circuit and receives dopaminergic innervation [42], [43].
The pathway initiates from the medium spiny neurons (MSN) in
the striatum carry dopamine D2 receptors [44–46] and regulates
sensorimotor gating, motor coordination, attention, learning and
antipsychotic pharmacology [47–51]. Kodsi and Swerdlow (1995)
showed that parts of globus pallidus, the ventral and caudal
pallidum, are involved in sensorimotor gating [50]. The preceding
report does not contradict the present finding although we did not
distinguish these subregions of the globus pallidus. The dopami-
nergic abnormality in the indirect pathway represents one of the
neuropathological features of this model and contributes to its
behavioral deficits.
Figure 8. Measurement of immobility in the bar-hang test
following pallidal infusion of the dopamine receptor antago-
nist and agonist. (A) Cannula placement was confirmed in fixed
brains, and four out of 63 rats were excluded from the final data analysis
due to incorrect cannula placement. The bar-hang test consisted of 3
blocks with 20-min intervals. Vehicle, raclopride (B; 0.5 and 2.0 mg per
site) or quinpirole (QUIN) (C; 10.0 mg per site) was bilaterally injected
into the globus pallidus of EGF and control (CON) rats after block #1. In
each session we measured the latency until one of the paws of rats was
removed from the horizontal bar (mean 6 SEM, N=8–9 rats each).
*P,0.05, **P,0.01, ***P,0.001, compared with vehicle-infused control
rats; +P,0.05, ++P,0.01, +++P,0.001, compared with the value of
session #1 by Fisher’s LSD. Note: The pallidal infusion of the D2-like
receptor agonist to control rats (green star) significantly reduced the
latency.
doi:10.1371/journal.pone.0025831.g008
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antagonism in the indirect pathway, however, several controver-
sies still remain; systemic administration of haloperidol failed to
result in clear PPI improvement in EGF-treated rats [26]. In this
context, neurobehavioral consequences of D2 receptor antagonism
may significantly differ depending upon the brain regions where
the antagonist acts [50]. Although we made the best efforts to
minimize the technical artifacts and variations of cannula
implantation, we cannot fully rule out aversive influences of the
microsurgery on behavioral testing. The regional specificity of the
drug actions should warrant future independent studies. As far as
we compared the animals in control and experimental groups that
equally received the surgery, however, the anti-dopaminergic
manipulations produced the consistent results in behavioral tests.
The inhibition of dopamine D2 receptor at presynaptic sites of
MSN fibers facilitates GABA release in the globus pallidus, leading
to motor dysfunction such as catalepsy [42], [52–55]. In
accordance with this cataleptic mechanism, our intrapallidal
infusion of the D2-like receptor antagonist to control rats resulted
in an increase in the catalepsy index while the D2-like receptor
agonist conversely decreased the catalepsy index. We observed a
similar D2-like receptor-dependency of the agonist and antagonist
in the PPI paradigm. These results suggest the possibility that these
behavioral deficits of EGF-treated rats involve the hyper-activation
of D2-like receptors. However, the abnormalities of the present
model in social behavior and pulse-alone startle appeared to be
distinct from the pallidal dopamine neuropathology. In this
context, EGF-treated rats should have the unrevealed structural
or phenotypic alteration(s) underlying these behavioral impair-
ments. Whether these impairments also involve the dopamine
system remains to be investigated.
Of note, alterations in pallidal morphology and abnormal
activation of this brain region are often implicated in schizophre-
nia. Brain imaging studies reveal pallidal structural abnormalities
in schizophrenia patients [56–61]. Functional imaging also
suggests an activation impairment in this brain region of patients
[62], [63]. These abnormalities might have any association with
the pallidal hyperdopaminergic states found in the present EGF
model, especially if excess dopamine exerts neurotrophic and cell
mitotic activities on pallidal cells and increases the tissue volume or
function [64].
Vulnerability of midbrain dopaminergic development to
neurotrophic cytokines
Schizophrenia animal models established by maternal immune
challenges or neonatal hypoxia appear to support the dopamine
hypothesis for schizophrenia although several controversies still
remain [65–67]. For example, the animal model established by
maternal challenge with bacterial lipopolysaccharide shows a long-
lasting increase in TH levels and dopamine turnover, at least, in
the nucleus accumbens [68], [69]. Perinatal asphyxia and viral
infection also result in distinct abnormalities in the dopamine
system [70–74]. Our preceding study suggests that neuregulin-1,
another ErbB receptor ligand, also induce several behavioral
abnormalities relevant to schizophrenia, when neuregulin-1 is
administered to newborn mice [4]. These findings indicate the
possibility that the phenotypic and functional abnormalities in
these immune/inflammatory models might involve EGF or other
ErbB ligand(s) acting on midbrain dopamine neurons at prenatal
or perinatal stages [25].
In conclusion, the developmental regulation of midbrain
dopaminergic neurons is more vulnerable against peripheral
cytokine signals than previously thought. The present results
indicate that perinatal and potentially prenatal exposure to EGF
or EGF-related cytokines may produce crucial and persistent
impact on dopaminergic innervation and function in the indirect
pathway of the basal ganglia circuit. In light of dopamine D2
receptor antagonism, which is commonly implicated in antipsy-
chotic pharmacology, the present cytokine model may help to
elucidate its antipsychotic mechanism as well as to validate the
dopamine hypothesis for schizophrenia.
Materials and Methods
Ethics statement
All of the animal experiments described were approved by the
Animal Use and Care Committee guidelines of Niigata University
(Approval No18 on April 26, 2010) and performed in accordance
with the guidelines of NIH-USA. Every effort was made to
minimize the discomfort of the animals in addition to the number
of animals used in the experiments.
Animals
Male newborn Sprague-Dawley rats (SLC Ltd., Hamamatsu,
Japan) were housed with a dam under a 12-h light/dark cycle
(lights on 8:00 a.m.) in a plastic cage (27664456205 mm). The
rats were allowed free access to food and water. After weaning
[postnatal day (PND) 20–30], rats were separated and housed with
2–3 rats per cage. Each adult animal (PND 56–94) was used in
each experiment. Naı ¨ve Sprague-Dawley rats (all male, PND 56–
70; SLC) were also used in control experiments. Recombinant
human EGF (Higeta Shouyu Co., Chiba Japan) was dissolved in
saline. EGF (0.875 mg/g) was administered subcutaneously (s.c.)
each day to half of the littermates during PND 2–10 [26]. Control
littermates received an injection of the same dose of cytochrome c
(control protein) on the same schedule. The dose of EGF used in
this study did not produce any apparent growth retardation in rats
and mice [26], [28]. Some of adult rats daily received risperidone
(1 mg/kg, i.p.; Janssen Pharmaceuticals Inc) or saline for 14 days.
Enzyme-linked immunosorbent assay (ELISA)
Rats were anesthetized with halothane, and brains were
removed and cut into 1-mm thick slices. Using published
boundaries [75], we identified and punched out each brain region
of interest. TH levels were measured using ELISA [10]. In brief,
brain tissues were homogenized in 10 volumes of homogenization
buffer [0.1 mM phenylmethanesulfonyl fluoride, 0.1 mM ben-
zethonium chloride, 1 mM benzamidine (Sigma Chemical Co., St.
Louis, MO), and 10 mg/ml aprotinin]. Brain homogenates were
centrifuged at 140006g for 20 min at 4uC, and the supernatants
were stored at 280uC until use. Protein concentrations were
determined using a Micro BCA kit (Pierce, Rockland, IL) with
bovine serum albumin (BSA) as a standard.
Tissue homogenates or striatal lysates (standards) were loaded
into ELISA plate wells coated with mouse monoclonal anti-TH
antibody (a gift from Dr. Hatanaka and Dr. Takei). Plates were
incubated with rabbit polyclonal anti-TH antibody (Chemicon,
Temecula, CA) followed by incubation with anti-rabbit IgG b-
galactosidase (1:1000, American Qualex, San Clemente, CA). The
fluorescence of the enzyme products from a reaction with 4-
methylumbelliferyl-b-D-galactoside (MUG, Sigma) was measured
using a microplate reader (COLONA electric Co., Ltd., Ibaraki,
Japan).
Immunoblotting
Each brain tissue was dissected as described above and
homogenized in 200 ml lysis buffer [2% sodium dodecylsulfate
(SDS), 10 mM Tris-HCl buffer (pH 7.4), 5 mM ethylenediamine-
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0.5 mM phenylarsine oxide], and boiled at 95uC for 5 min. After
centrifugation at 12000 rpm for 20 min, the supernatant was
harvested. The supernatant was mixed with 56 sample buffer
[0.31 M Tris-HCl (pH 6.8), 10% SDS, 50% glycerol, 25% 2-
mercaptoethanol] and boiled at 95uC for 5 min. Denatured
protein samples were subjected to 7.5% SDS-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane
(Schleicher and Schull, Dassel, Germany) by electrophoresis. The
membrane was probed with anti-TH (1:2000, Chemicon), anti-
vesicular monoamine transporter 2 (VMAT2) (1:1000, Chemicon),
anti-dopamine-beta-hydroxylase (DbH) (1:500, Chemicon), anti-
dopamine D1 receptor (1:1000, Sigma) or anti-D2 receptor
(1:1000, Chemicon) antibodies. After washing, membrane immu-
noreactivity was detected using anti-rat, anti-rabbit, or anti-mouse
immunoglobulin antibody conjugated to horseradish peroxidase
(Jackson Immunoresearch Laboratory, West Grove, PA) followed
by a chemiluminescence reaction (ECL kit, GE Health Science
Inc., Tokyo, Japan) and exposure to X-ray films. Film images
carrying a liner range of darkness of bands were subjected to film
scanning and converted to the 8-bit digital data. Densitometric
quantification of band intensity was performed with the free
software Image J (National Institutes of Health, USA).
Immunohistochemistry
Rats were anesthetized with halothane, perfused transcardially
for 7 min with phosphate-buffered saline (150 mM NaCl, 0.1 M
sodium phosphate; pH 7.5) followed by 4% paraformaldehyde in
phosphate-buffered saline. Brains were removed and post-fixed in
the same fixation solution for 24 h at 4uC. Fixed brains were
immersed in 30% sucrose solution for 3–5 days, and frozen in resin
(Tissue-Tek, Sakura Finetek U.S.A. Inc. Torrance, CA). Sections
(40 mm) were cut with a cryostat (CM1510, Leica, Nussloch,
Germany). After rinsing in Tris-buffered saline [TBS; 0.1 M Tris-
HCl (pH 7.4), 150 mM NaCl] containing 0.2% Triton X-100,
sections were pretreated with 6% BSA and 0.2% Triton X-100 in
TBS and then incubated with anti-TH antibody (1:1000,
Chemicon) in TBS containing 3% BSA and 0.2% Triton X-100
for 48–72 h at 4uC. After rinsing in TBS/0.2% Triton X-100
three times, sections were incubated with biotinylated anti-rabbit
immunoglobulin antibody (1:200, Jackson Immunoresearch Lab-
oratory). Immunoreactivity was visualized using a Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA) using diamino-
benzidine as a substrate.
Determination of monoamine contents
Each brain region was homogenized in 0.1 M perchloric acid
containing 0.1 mM EDTA, and 100 nM isoproterenol. After
centrifugation at 12000 rpm for 20 min, the supernatants and
pellets were harvested. Concentrations of dopamine and its
metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homo-
vanillic acid (HVA), in supernatants were analyzed by HPLC-
electrochemistry [4]. The mobile phase containing 50 mM
trisodium citrate (pH 3.2), 25 mM NaH2PO4, 10 mM diethyl-
amine, 0.03 mM EDTA, 2.5 mM 1-octane sulfonic acid sodium
salt, 6% methanol, 1% dimethylacetamide was delivered at
0.5 mL/min. Monoamines were separated on an analytical HPLC
column (CA-50DS, 4.66150 mm, Eicom, Kyoto, Japan) and
detected with a graphite electrode (WE-3G, Eicom) to which
+700 mV was applied. Data analysis was performed with a data
acquisition computer (Powerchrom, Eicom). Tissue pellets were
homogenized in 0.5 N NaOH and subjected to protein determi-
nation with a Micro BCA kit (see above). Tissue monoamine
contents were normalized with protein concentrations.
Local drug administration to the globus pallidus
Control and EGF-treated rats (PND 56–70) were anesthetized
with sodium pentobarbital (65 mg/kg, i.p.). After confirming
deep anesthesia, a rat was mounted on a stereotaxic apparatus
with an incisor bar set at 3.3 mm below the interaural line. The
skull was exposed and two holes were drilled for bilateral
implantation of guide cannulae (23 G stainless-steel pipes) into
the GP. The stereotaxic coordinates were 0.9 mm anterior,
63.0 mm lateral from the bregma, and 4.5 mm below the dura
mater. After allowing the rat at least 10 days of recovery from
surgery, a 30-G needle connected to Teflon tubing and a
Hamilton syringe was placed 2 mm below the tip of the guide
cannula. The drug (0.5 ml) was injected over a period of 30 sec,
and the needle left in place for an additional 30 sec. Rats were
placed in their home cage for 5–15 min, to allow for local
diffusion of the drug; the rats were then subjected to behavioral
tests (see below). When rats received reserpine, rats were placed
in their home cage for 120 min to deplete the local dopamine
pool. The cannula position was confirmed after the completion of
the behavioral tests (see below).
Reserpine (Daiichi Sankyo Pharmaceutical Inc., Tokyo, Japan)
was dissolved in phosphate-buffered solution (pH 4.0) containing
3 mg/mL DL-methionine and 70 mg/mL propylene glycol.
Conventional dopamine receptor ligands, SCH23390, raclopride
and quinpirole, were all obtained from Sigma and dissolved in
10% dimethyl sulfoxide (DMSO) in saline (vehicle).
Microdialysis
Rats were anesthetized with sodium pentobarbital (65 mg/kg
i.p.) and mounted in a stereotaxic apparatus. The skull was
exposed and a hole was drilled for unilateral implantation of a
guide cannula (AG-8, Eicom) into the GP. The stereotaxic
coordinates were 0.9 mm anterior; 3.0 mm lateral from the
bregma, and 4.8 mm below the dura mater. After allowing the rat
at least 10 days of recovery from surgery microdialysis experiments
were performed.
The microdialysis probe (2 mm active area, A-I-8-02, Eicom)
was connected to Teflon tubing (0.65 mm o.d., 0.12 mm i.d.;
Bioanalytical Systems Inc., West Lafayette, IN). The rat was
perfused with artificial cerebrospinal fluid (pH 7.0) containing
147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, and 0.5 mM
MgCl2 at a flow rate of 0.7 mL/min. Dialysate was discarded to
obtain a steady state for at least 18 h after implantation of the
probe, and then dialysate samples were collected every 30 min.
The first five fractions were collected to determine basal levels of
dopamine. The perfusion medium was switched to the medium
containing a high concentration of potassium (80 mM KCl,
69.7 mM NaCl, 1.2 mM CaCl2, 0.5 mM MgCl2; pH 7) for
60 min (for two fractions). The perfusion medium was then
switched back to the original medium and five fractions were
additionally collected. In all, total 12 fractions were collected.
Dopamine in the dialysates was determined by HPLC with
electrochemical detection. The mobile phase containing 48 mM
citric acid, 24 mM sodium acetate, 10 mM NaCl, 0.5 mM
EDTA, 2.5 mM SDS, and 16% acetonitrile (pH 4.8) was
delivered at 50 mL/min. Dopamine was separated on an
analytical column (BDS Hypersil C18 16100 mm, Thermo
Fisher Scientific, Yokohama, Japan) and detected with a 3 mm
glassy carbon electrode detector (Unijet flow cell; Bioanalytical
Systems Inc.) to which +550 mV was applied. Data analysis was
performed with the analysis software (Epsilon LC; Bioanalytical
Systems Inc.). Data were not compensated with the recovery
rate.
Pallidal Dopamine Increase and Behavioral Deficits
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25831Confirmation of cannula positioning
After local drug injection or microdialysis, rats were deeply
anesthetized with halothane and decapitated. Brains were quickly
removed and fixed in 4% paraformaldehyde for 3 days. Fixed
brains were cut into 50-mm sections using a vibratome (Dosaka
EM Ltd., Kyoto, Japan). Each section was stained with 0.5%
cresyl violet solution. The location of a microdialysis probe or
injection needle was determined under a microscope according to
a stereotaxic atlas [75]. Animals that exhibited incorrect cannula
placement were removed from the data analysis.
Measurement of acoustic startle and prepulse inhibition
of startle response
Acoustic startle amplitude was measured in a startle chamber
(SR-Lab Systems, San Diego Instruments, San Diego, CA) [34].
Rats were placed into a startle chamber with 70-dB background
noise. Five minutes later, the startle amplitude was recorded in a
session that included multiple trial types: (i) a 120-dB 40-ms noise
burst presented alone (pulse); (ii–iv) 40-ms 120-dB noise burst
following prepulses by 100 ms (20-ms noise burst) that were 5, 10,
and 15 dB above background noise (i.e., 75-, 80-, 85-dB prepulse,
respectively); and (v) no stimulus (background noise alone). The
percentage PPI of startle responses was calculated as: 1002[(startle
response on prepulse-pulse stimulus trials – no stimulus trials)/
(pulse-alone trials – no stimulus trials)]6100. To match the
magnitude of pulse alone startles between groups, a 120-dB noise
burst was replaced with a 110-dB noise burst in some experiments.
Analysis of locomotor activity
Side effects of reserpine were estimated by monitoring
spontaneous locomotor activity under novel conditions. Reser-
pine-infused rats were placed in an open field box (45 cm
length645 cm width630 cm height, MED Associates, St. Albans,
VA, USA) under a moderate light level (200 Lx). Line crossings
and rearing counts were measured by photo-beam sensors (25 mm
intervals for horizontal axis and 150 mm for vertical axis).
Social interaction test
The index for social interaction of rats was measured according
to Futamura et al. (2003) [26]. Following the above locomotor test,
reserpine- or vehicle-infused rats were exposed to an unfamiliar
male rat that was housed in another cage, and was age, body-
weight, and gender-matched. All tests were videotaped and scored
in blind. Scoring of social interaction times and duration was
based on sniffing behaviors, defined as active chasing of the
partner, shaking the nose near the partner, and contacting the
partner with the nose.
Measurement of immobilization levels in the bar-hang
test
Immobilization levels and the cataleptic effects of drugs were
measured using a bar-hang test method [76]. In the bar-hang test,
the front paws of the rat were gently placed on a horizontal metal
bar (5 mm diameter) and placed 10 cm above ground level. The
test was terminated when the paw of animal was released from the
bar or 300 sec had passed, and the total time until the animals
removed the paw from the bar was recorded. Rats were subjected
to three blocks (separated by 20-min intervals) of three trials.
Scores at the three different time blocks (after 1-h acclimation, 20
and 40 min after drug infusion) were monitored for comparison
purposes.
Statistical analysis
All data are expressed as means 6 SEM. Statistical differences
in the behavioral data were determined by analysis of variance
(ANOVA). When univariate data were obtained from two groups,
two-tailed t-test was used for comparison. Behavioral scores were
initially subjected to factorial ANOVA using neonatal EGF
treatment (two levels) and local drug infusion (two or three levels)
as between-subjects factors, and prepulse magnitude (three levels)
or test session (two levels) as a within-subjects factor. As the initial
analyses yielded a significant factorial interaction, data were
subjected to a Fisher’s LSD post-hoc test with or without repeated
measure. The interaction of a within-subjects factor with a
between-subjects factor was estimated by multivariate analysis of
variance (MANOVA). Individual statistical differences between
data points are shown in the figures. Correlations between
dopamine release and PPI were examined by Pearson’s correlation
analysis. A p value less than 0.05 was regarded as statistically
significant. Statistical analyses were performed using StatView
software (SAS Institute Inc., Cary, NC, USA). N values in
parentheses represent the number of animals used in each group.
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